Solid forms of a compound for modulating cot
AssigneeGilead Sciences, Inc.
InventorsErnest A. Carra, Lina Chan, Roland D. Saito
Life of this patent
Estimating the term…
Abstract
Disclosed herein are solid forms of a compound useful for modulating Cot. The disclosure also relates to pharmaceutical compositions containing one or more of the solid forms disclosed herein, as well as methods of using the solid forms in the treatment of conditions mediated by Cot. The disclosure also relates to methods for obtaining such solid forms.
Claims73
A solid form of Formula I Form II, wherein the Formula I has the structure:
The solid form of claim 0, characterized by an X-ray diffraction pattern having 2θ-reflections at 7.4, 9.4, and 10.6 degrees 2θ, plus or minus 0.2 degrees 2θ.
The solid form of claim 0, characterized by an X-ray diffraction pattern further comprising 2θ-reflections at 8.8, 12.3, and 26.1 degrees 2θ, plus or minus 0.2 degrees 2θ.
A solid form of Formula I Form III, wherein the Formula I has the structure:
The solid form of claim 0, characterized by an X-ray diffraction pattern having 2θ-reflections at 7.8, 9.8, and 10.7 degrees 2θ, plus or minus 0.2 degrees 2θ.
The solid form of claim 0, characterized by an X-ray diffraction pattern further comprising 2θ-reflections at 8.9, 12.5, and 20.1 degrees 2θ, plus or minus 0.2 degrees 2θ.
A solid form of Formula I Form IV, wherein the Formula I has the structure:
The solid form of claim 0, characterized by an X-ray diffraction pattern having 2θ-reflections at 8.0, 18.1, and 20.0 degrees 2θ, plus or minus 0.2 degrees 2θ.
The solid form of claim 0, characterized by an X-ray diffraction pattern further comprising 2θ-reflections at 9.0, 9.9, and 10.8 degrees 2θ, plus or minus 0.2 degrees 2θ.
A solid form of Formula I Form VII, wherein the Formula I has the structure:
The solid form of claim 0, characterized by an X-ray diffraction pattern having 2θ-reflections at 6.2, 8.4, and 22.6 degrees 2θ, plus or minus 0.2 degrees 2θ.
The solid form of claim 0, characterized by an X-ray diffraction pattern further comprising 2θ-reflections at 10.3, 10.9, and 11.7 degrees 2θ, plus or minus 0.2 degrees 2θ.
A solid form of Formula I Form IX, wherein the Formula I has the structure:
The solid form of claim 0, characterized by an X-ray diffraction pattern having 2θ-reflections at 7.2, 5.8, and 5.7 degrees 2θ, plus or minus 0.2 degrees 2θ.
The solid form of claim 0, characterized by an X-ray diffraction pattern further comprising 2θ-reflections at 10.7, 15.3, and 17.1 degrees 2θ, plus or minus 0.2 degrees 2θ.
A solid form of Formula I S-Mandelate Form A, wherein the Formula I has the structure:
The solid form of claim 0, characterized by an X-ray diffraction pattern having 2θ-reflections at 5.5, 5.7, and 6.3 degrees 2θ, plus or minus 0.2 degrees 2θ.
The solid form of claim 0, characterized by an X-ray diffraction pattern further comprising 2θ-reflections at 11.4, 16.6, and 20.8 degrees 2θ, plus or minus 0.2 degrees 2θ.
A solid form of Formula I S-Mandelate Form B, wherein the Formula I has the structure:
The solid form of claim 0, characterized by an X-ray diffraction pattern having 2θ-reflections at 5.7, 6.2, and 22.6 degrees 2θ, plus or minus 0.2 degrees 2θ.
The solid form of claim 0, characterized by an X-ray diffraction pattern further comprising 2θ-reflections at 8.0, 8.4, and 11.7 degrees 2θ, plus or minus 0.2 degrees 2θ.
A solid form of Formula I R-Mandelate Form A, wherein the Formula I has the structure:
The solid form of claim 0, characterized by an X-ray diffraction pattern having 2θ-reflections at 5.7, 5.4, and 16.5 degrees 2θ, plus or minus 0.2 degrees 2θ.
The solid form of claim 0, characterized by an X-ray diffraction pattern further comprising 2θ-reflections at 6.2, 7.8, and 11.5 degrees 2θ, plus or minus 0.2 degrees 2θ.
A solid form of Formula I R-Mandelate Form B, wherein the Formula I has the structure:
The solid form of claim 0, characterized by an X-ray diffraction pattern having 2θ-reflections at 6.2, 8.3, and 22.4 degrees 2θ, plus or minus 0.2 degrees 2θ.
The solid form of claim 0, characterized by an X-ray diffraction pattern further comprising 2θ-reflections at 15.9, 16.3, and 17.0 degrees 2θ, plus or minus 0.2 degrees 2θ.
The pharmaceutical composition of claim 0, further comprising one to three additional therapeutic agents.
The pharmaceutical composition of claim 0, wherein at least one of the additional therapeutic agents is active against an inflammatory disease.
The pharmaceutical composition of claim 0, wherein the unit dosage form is a tablet.
(canceled)
(canceled)
A pharmaceutical composition comprising
- a therapeutically effective amount of a mixture of a solid form of Formula I Form II, a solid form of Formula I Form III, and a solid form of Formula I Form IV;
- and
- a pharmaceutically acceptable carrier, wherein the Formula I has the structure:
Dependencies are inferred from the claim text.